WithdrawnPhase 2

Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML

Stopped: The P.I deceased.

United States0Started 2001-02-13

Plain-language summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of amifostine and high-dose combination chemotherapy in treating patients with acute myeloid leukemia or chronic myelogenous leukemia.

Who can participate

Age range18 Years – 120 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕Not identified by the protocol

What they're measuring

Effectiveness of amifostine and high-dose combination chemotherapy in treating patients with acute myeloid leukemia or chronic myelogenous leukemia

Timeframe: 6 months

Trial details

NCT IDNCT00003407

SponsorRush University Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2004-04-07

View on ClinicalTrials.gov More Drug/Agent Toxicity by Tissue/Organ trials